Vortioxetine

• Description:

  Vortioxetine (Lu AA 21004) is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial agonist of 5-HT1B (Ki: 15 nM, 33 nM) [1][2].

• Product Name Alternative:

  Lu AA 21004

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  5-HT Receptor; Serotonin Transporter

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Vortioxetine.html

• Purity:

  98.61

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  CC1=CC=C(SC2=CC=CC=C2N3CCNCC3)C(C)=C1

• Molecular Formula:

  C18H22N2S

• Molecular Weight:

  298.45

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Bang-Andersen B, et al. Discovery of 1-[2- (2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004) : a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54 (9) :3206-21.|[2]Guilloux JP, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013 May 28;73C:147-159.|[3]Theunissen EL, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013 Jun;93 (6) :493-501.|[4]Rothschild AJ, et al. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22 (12) :858-66.|[5]Mrk A, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340 (3) :666-75.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  5-HT1 Receptor;5-HT3 Receptor;5-HT7 Receptor; lactoferrin; mLAG-3; MUC3

• Citation 01:

  Antioxidants (Basel) . 2024 May 29;13 (6) :667.|Biomedicines. 2022 Jun 3;10 (6) :1318.|bioRxiv. 2024 Feb 9:2024.02.08.579543.|bioRxiv. 2025 February 08.|Eur Arch Psychiatry Clin Neurosci. 2023 Mar;77 (3) :149-159.|Eur J Pharmacol. 2025 Jul 5:998:177460.|Nature. 2023 Dec;624 (7992) :672-681.|Neurobiol Dis. 2024 Oct 1:200:106651.|Psychiat Res. November 2022, 114838.|Psychiatry Res. 2022 Nov:317:114838.|Mol Pharmacol. 2023 Nov;104 (5) :230-238.

• CAS Number:

  508233-74-7